Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anxiety Disorders
Research conducted at Columbia University has provided new information about anxiety disorders
May 12th, 2008
"Generalized anxiety disorder (GAD), a prevalent and chronic illness, is associated with dysregulation in both serotonergic and noradrenergic neuro-transmission. Our study examined the efficacy, safety, and tolerability of duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, for short-term treatment of adults with GAD," investigators in the United States report. "In a 10-week, double-blind, progressive-titration, flexible-dose trial, 327 adult outpatients with a DSM-IV-defined GAD diagnosis were randomized to duloxetine 60-120 mg (DEX, N = 168) or placebo (PLA, N = 159) treatment. The primary efficacy measure was mean change from baseline...
Source: Biotech Business Week (2008-05-12)
|
